1. Home
  2. |Insights
  3. |IRS Announces Inflation-Adjusted Dollar Limits for 2004

IRS Announces Inflation-Adjusted Dollar Limits for 2004

Client Alert | 1 min read | 12.22.03

In IR-2003-122, the IRS announced the limitations applicable to contributions and benefits under various employee benefit provisions of the Code for 2004, as adjusted for changes in the cost of living. The 2004 limits are as follows:

Item
2004
2003
Maximum annual annuity payable from a tax-qualified defined benefit pension plan at age 65
$165,000
$160,000
Maximum "annual addition" to a participant's account under a tax-qualified defined contribution plan
$41,000
$40,000
Elective Deferrals under Code Section 402(g)
$13,000
$12,000
SIMPLE plan elective contributions
$9,000
$8,000
(2003)
Section 401(a)(17) Limit on annual amount of a participant's compensation that can be taken into account for contribution or benefit purposes under a tax-qualified retirement plan
$205,000
$200,000
Section 401(a)(17) compensation limit with COLA adjustment
$305,000
$300,000
Compensation threshold for definition of "highly compensated employee"
$90,000
$90,000
Compensation limit for determining "key employees" for top-heavy plan purposes
$130,000
$130,000
Compensation limit for definition of "control employee for fringe benefit valuation purposes
$80,000
$80,000
Compensation limit for definition of "control employee for fringe benefit valuation purposes
$80,000
$80,000
ESOP five-year distribution limit
$830,000
$810,000

 

Insights

Client Alert | 6 min read | 09.03.26

FDA Seeks Input for Regulating GenAI-Powered Medical Devices

The U.S. Food & Drug Administration (FDA) is seeking feedback on a regulatory framework that could be used to evaluate generative artificial intelligence (GenAI)-enabled medical devices. Such devices could create new types of risks because their outputs can vary and evolve, unlike more traditional software-enabled devices. An August 18, 2026, discussion paper (“Considerations for the regulation of GenAI-enabled medical devices”) discusses potential regulatory considerations for GenAI-enabled medical devices. ...

View All Insights